The idiopathic interstitial pneumonias (IIPs) are a diverse group of parenchymal lung diseases with varied treatment approaches and prognoses (1). Of the IIPs, usual interstitial pneumonia (UIP), the histopathologic correlate of idiopathic pulmonary fibrosis (IPF), is the most common, and associated with the worst prognosis. The clinical course of patients with IPF is variable and can display long periods of stability, a steady gradual decline, and/or periods of acute deterioration (2, 3). This unpredictable nature of UIP/IPF highlights the importance of identifying factors that can help refine the prognosis for patients at the time of initial diagnosis.
In this issue of the Journal (pp.
One of the most striking findings of this study is the variable HRCT appearance of UIP despite very rigid histopathologic criteria. This study excluded 51 cases that were previously called UIP based on the lack of a confident diagnosis of UIP at biopsy. I would have expected the rigid inclusion criteria to define a more homogeneous patient population with similar HRCT features. Interestingly, only approximately one-third of HRCTs showed definite IPF and approximately one-third suggested an alternative diagnosis, such as NSIP, or were unclassifiable! We also found a high prevalence of histopathologic UIP in patients with an HRCT appearance of indeterminate or NSIP (5). These studies highlight the critical importance of a surgical lung biopsy in making an accurate diagnosis in patients without definite HRCT appearance of UIP, even when an alternative diagnosis, such as NSIP, is suspected.
This study also sheds additional light on the role of HRCT in determining prognosis for patients with IPF/UIP. The survival of patients within each HRCT category was statistically similar, although the median survival was shortest for the definite UIP group (35 mo), intermediate for the consistent with UIP group (43 mo), and longest for the alternative diagnosis group (112 mo). This is similar to previous findings that patients with IPF/UIP and a definite HRCT appearance of UIP have a shorter median survival (21 mo) compared with those with an indeterminate/NSIP-appearing HRCT (69 mo) (5). The lack of statistical significance in the current study could be due to limited sample size or selection bias either through the selection of cases for biopsy or due to the large number of patients previously diagnosed with UIP who were excluded (n = 65) (4). Investigators in the current study also performed a detailed, quantitative analysis of HRCT features. In multivariate modeling, the extent of traction bronchiectasis and quantity of fibrosis were significant predictors of subsequent mortality. The overall extent of fibrosis on HRCT has previously been associated with increased risk of subsequent mortality, although traction bronchiectasis was not evaluated (6). It is uncertain if knowledge of the histopathologic diagnosis by radiologists in the current study influenced the HRCT diagnosis and/or quantification of features. However, the similar trends in these studies (4, 6) support a conclusion that HRCT appearance and quantification of features, particularly fibrosis, can be useful to stratify the risk of subsequent mortality for patients with IPF/UIP.
The work by Sumikawa and colleagues highlights the variable appearance of IPF/UIP on HRCT as well as the ability of HRCT appearance and quantification of features to predict the risk of subsequent mortality. Further work is required to define how scoring of these HRCT features would fare in predicting mortality in community settings in which disagreement between academic physicians is likely to be present (7). Additional studies combining HRCT features with elements of pulmonary physiology, such as vital capacity, diffusing capacity for carbon monoxide, desaturation, and pulmonary hypertension are also needed.
|1.||American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277–304.|
|2.||Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636–643.|
|3.||Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963–967.|
|4.||Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, Kondoh Y, Ogura T, Arakawa H, Fujimoto K, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008;177:433–439.|
|5.||Flaherty K, Thwaite E, Kazerooni E, Gross B, Toews G, Colby T, Travis W, Mumford J, Murray S, Flint A, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143–148.|
|6.||Lynch DA, David Godwin J, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488–493.|
|7.||Flaherty KR, Andrei AC, King Jr TE, Raghu G, Colby TV, Wells A, Bassily N, Brown KK, du Bois R, Flint A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007;175:1054–1060.|